Similar Search Results

Hospital Reimbursement Price Cap for Cancer Drugs: The French Experience in Controlling Hospital Drug Expenditures

Degrassat-Théas, A. Degrassat-Thas; Bensadon, M.; Rieu, C. - In: PharmacoEconomics 30 (2012) 7, pp. 565-573

Background:Background: In 2005, the French Government implemented a new way of financing high-cost drugs for hospitals in order to promote innovation. Such drugs are gathered on a positive list, established by the Ministry of Health, with a reimbursement price cap. Hospitals still negotiate with...

Persistent link: https://www.econbiz.de/10011005079

Recent National and Regional Drug Reforms in Sweden: Implications for Pharmaceutical Companies in Europe

Wettermark, Bjorn; Godman, Brian; Andersson, Karolina; … - In: PharmacoEconomics 26 (2008) 7, pp. 537-550

With an aging population and increased prevalence of chronic diseases, such as obesity and diabetes mellitus, drug reforms are needed across Europe to ensure the continued provision of comprehensive healthcare. It is also a challenge, with the limited resources available, to fund new innovative...

Persistent link: https://www.econbiz.de/10005243086

Pricing Human Papillomavirus Vaccines: Lessons from Italy

Garattini, Livio; van de Vooren, Katelijne; Curto, … - In: PharmacoEconomics 30 (2012) 3, pp. 213-217

Persistent link: https://www.econbiz.de/10009493380

Value of Information and Pricing New Healthcare Interventions

Willan, Andrew R.; Eckermann, Simon - In: PharmacoEconomics 30 (2012) 6, pp. 447-459

Previous application of value-of-information methods to optimal clinical trial design have predominantly taken a societal decision-making perspective, implicitly assuming that healthcare costs are covered through public expenditure and trial research is funded by government or donation-based...

Persistent link: https://www.econbiz.de/10010548289

Reflections on the Changing Face of German Pharmaceutical Policy: How Far is Germany from Value-Based Pricing?

Gerber, Andreas; Stock, Stephanie; Dintsios, … - In: PharmacoEconomics 29 (2011) 7, pp. 549-553

Persistent link: https://www.econbiz.de/10010614333

Value-Based Pricing: Incentive for Innovation or Zero Net Benefit?

Hughes, Dyfrig A. - In: PharmacoEconomics 29 (2011) 9, pp. 731-735

Persistent link: https://www.econbiz.de/10010614367

Availability of and Access to Orphan Drugs: An International Comparison of Pharmaceutical Treatments for Pulmonary Arterial Hypertension, Fabry Disease, Hereditary Angioedema and C...

Blankart, Carl Rudolf.; Stargardt, Tom; Schreyogg, … - In: PharmacoEconomics 29 (2011) 1, pp. 63-82

Background: Market authorization does not guarantee patient access to any given drug. This is particularly true for costly orphan drugs because access depends primarily on co-payments, reimbursement policies and prices. The objective of this article is to identify differences in the availability...

Persistent link: https://www.econbiz.de/10010614375

Effects of Reference Pricing in Pharmaceutical Markets: A Review

Galizzi, Matteo Maria.; Ghislandi, Simone; Miraldo, Marisa - In: PharmacoEconomics 29 (2011) 1, pp. 17-33

introduction of reference pricing (RP) policies in Organisation for Economic Co-operation and Development (OECD) countries. We …

Persistent link: https://www.econbiz.de/10010614402

Financial Effects of Pharmaceutical Price Regulation on R&D Spending by EU versus US Firms

Golec, Joseph; Vernon, John A. - In: PharmacoEconomics 28 (2010) 8, pp. 615-628

EU countries closely regulate pharmaceutical prices, whereas the US does not. This paper shows how price constraints affect the profitability, stock returns and R&D spending of EU and US firms. Compared with EU firms, US firms are more profitable, earn higher stock returns and spend more on R&D....

Persistent link: https://www.econbiz.de/10008465562

Impact of European Pharmaceutical Price Regulation on Generic Price Competition: A Review

Puig-Junoy, Jaume - In: PharmacoEconomics 28 (2010) 8, pp. 649-663

cap) and by setting the maximum reimbursement rate, especially by means of reference pricing systems. We analyse current … reimbursement rate, particularly through reference pricing and similar tools, on dynamic price competition between generic …/or regulation of the reimbursement rate (reference pricing or similar systems) on price dynamics, corresponding to pharmacy sales …

Persistent link: https://www.econbiz.de/10008465564